Full-length recombinant protein corresponding to human tPA (wild-type sequence)
Tissue-type plasminogen activator (tPA) circulating in plasma exists in free forms as well as in tPA-inhibitor complexes. The underlying biochemical mechanism governing coagulation and fibrinolysis involves a controlled cascade of proteolytic reactions characterized by the conversion of serine protease zymogens to enzymes. Depending upon the initiating stimulus, the physiological outcome of these reactions is blood clot formation/dissolution (1-4). The relative concentrations of serine protease zymogen, enzyme, or enzyme-inhibitor complex in circulation will vary in accord with the state of vascular damage. Many conventional antigen-based clotting factor-specific immunoassays do not distinguish between zymogen and enzyme. Applications: Suitable for use in ELISA, Western Blot and Immunohistochemistry. Other applications not tested. Recommended Dilutions: Optimum dilutions to be determined by researcher. Storage and Stability: May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Reinheit:
Purified by Protein A affinity chromatography.
Formulierung:
Supplied as a liquid in 0.05M sodium phosphate, 0.1M sodium chloride, 1mM EDTA, pH 6.6.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
